Hormonal
High dietary intake of linoleic acid (an n-6 fatty acid) promotes adipose tissue development and obesity in early life by being converted to arachidonic acid, which activates prostacyclin signaling to stimulate preadipocyte differentiation, whereas n-3 fatty acids inhibit this pathway.
The type of fat you eat matters for your body composition, especially during early development. Diets high in n-6 fatty acids (like corn/soy oils) may promote fat storage through specific hormonal pathways, while n-3 fatty acids (fish/flax oils) may inhibit this process. For adults, this suggests prioritizing n-3 sources and balancing n-6 intake, though the strongest evidence is for developmental stages.
High fat intake is associated with fat mass gain through fatty acid activation of peroxisome proliferator-activated receptors... arachidonic acid (C20:4, n-6) promoted substantially the differentiation of clonal preadipocytes... During the pregnancy-lactation period, mother mice were fed either a high-fat diet rich in linoleic acid... Body weight from weaning onwards, fat mass... were higher with LO diet than with LO/LL diet.
Why this rating
Strong mechanistic evidence in mice with genetic knockouts (ip-r-/-) confirming the pathway, but extrapolation to human obesity requires caution regarding dosage and metabolic differences.
Source
Arachidonic acid and prostacyclin signaling promote adipose tissue development: a human health concern?
Florence Massiéra et al. · Journal of Lipid Research · 2003
DOI 10.1194/jlr.m200346-jlr200
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →